1 – 3 of 3
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
COMBAT-MS : A Population-Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab
2024) In Annals of Neurology(
- Contribution to journal › Article
- 2020
-
Mark
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
(
- Contribution to journal › Article
-
Mark
Infection Risks among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
(
- Contribution to journal › Article